BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Andelyn Biosciences partners with Amplo Biotechnology to advance AAV gene therapies for neuromuscular junction disorders

August 21, 2025 | News | By Ankit Kankar | ankit.kankar@mmactiv.com

Collaboration leverages Andelyn's suspension AAV CuratorÃ?Â® platform to deliver scalable clinical-grade material, accelerating Amplo's mission to develop transformative treatments for patients worldwide.



Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Amplo Biotechnology, a pioneer in adeno-associated virus (AAV) regenerative medicines for neuromuscular junction (NMJ) affecting conditions. The partnership will provide scalable manufacturing of clinical-grade AAV material, leveraging Andelyn's suspension AAV Curator® platform.

Diseases of the NMJ typically result in muscle weakness with severe cases requiring the use of respiratory support, the use of wheelchair for ambulation, and/or tube feeding. In some cases, NMJ disorders can be life-threatening. Genetic NMJ diseases are typically diagnosed in early childhood but can also manifest in adolescence or adulthood.

Andelyn Biosciences suspension AAV Curator® platform is a highly characterized, scalable, suspension AAV platform that leverages a data-driven approach to adapt and optimize customer processes while providing a pathway to cGMP and commercial manufacturing. By adopting this platform, Amplo Biotechnology aims to advance its AAV gene therapy programs toward clinical evaluation, focusing on the safety and efficacy required for upcoming trials.

"As a leading clinical and commercial CDMO, we are honored to support Amplo Biotechnology's efforts to bring hope to patients affected by debilitating NMJ diseases," said Matt Niloff, Chief Commercial Officer at Andelyn Biosciences. "Our Curator® platform and end-to-end capabilities are designed to help partners achieve key development and clinical milestones."

Amplo Biotechnology stated that this partnership strengthens its ability to deliver high-quality AAV material and supports its mission to develop transformative therapies for families impacted by genetic NMJ disorders worldwide.

Andelyn is enabling the progression of life-altering cell and gene therapies for both rare and prevalent diseases with the highest quality standards and scalable end-to-end development and manufacturing capabilities at its Columbus, Ohio facilities. By collaborating with leading organizations such as Amplo Biotechnology, Andelyn is at the forefront of advancing life-changing gene therapies. This partnership not only underscores Andelyn's commitment to innovation but also highlights its role in transforming the landscape of healthcare through the development of groundbreaking treatments. ?